<DOC>
	<DOCNO>NCT00110955</DOCNO>
	<brief_summary>The purpose study compare effect darbepoetin alfa placebo treatment anemia subject non-myeloid malignancy receive multicycle chemotherapy .</brief_summary>
	<brief_title>Treatment Anemia Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects nonmyeloid malignancy At least 12 additional week cyclic cytotoxic chemotherapy anticipate regardless schedule Hemoglobin concentration le 11.0 g/dL within 24 hour randomization Adequate serum folate vitamin B12 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Of legal age time write informed consent obtain Known history seizure disorder Known primary hematologic disorder cause anemia nonmyeloid malignancy Unstable/uncontrolled cardiac condition Clinically significant inflammatory disease Other diagnosis related cancer cause anemia Inadequate renal liver function Iron deficiency Known positive test HIV infection Previously suspect confirmed neutralizing antibody rHuEPO Received 2 red blood cell ( RBC ) transfusion within 4 week randomization ; RBC transfusion within 14 day randomization ; plan RBC transfusion randomization study day 1 Received erythropoietic therapy within 4 week study day 1 plan erythropoietic therapy randomization study day 1 Other investigational procedure Currently enrol yet complete least 30 day since end investigational device drug trial ( ) , subject receive investigational agent ( ) Pregnant breast feed Not use adequate contraceptive precaution Previously randomize study Known hypersensitivity product administer Concerns subject 's compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Non-myeloid malignancy</keyword>
	<keyword>Chemotherapy-induced anemia</keyword>
</DOC>